QurAlis to in-license lead excitotoxicity targeted ALS therapeutic candidates from Lilly Cambridge, MA, July 01, 2020 — QurAlis Corporation, a biotech company focused on developing precision medicines for amyotrophic lateral…
Read MoreCAMBRIDGE, Mass., May 13, 2020— QurAlis Corporation, a biotech company focused on developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced the raise of a…
Read MoreQurAlis has won the Pfizer Golden Ticket! to read more click here.
Read MoreThe man had come for a third opinion. Other doctors had told him he had amyotrophic lateral sclerosis, or ALS, a neuromuscular disease that causes progressive paralysis, but he didn’t…
Read MoreWe successfully generated a crystal structure of one of our early lead molecules in complex with our molecular target. This structure is currently being used to design new compounds.
Read More
CAMBRIDGE, Mass., April 5, 2018. QurAlis Corporation, a new private biotech company focused on developing precision solutions to cure ALS, today announced the addition of biotech investors MP Healthcare Venture…
Read More
CAMBRIDGE, Mass., Dec. 15, 2017 QurAlis was chosen by an Amgen internal committee and live audience members at a “Quick Pitch” event hosted by Amgen at its Cambridge R&D and Operations…
Read More